http://www.prestashopmanager.com/useful-articles/prestashop-export-products Watch this video to see how easy it is to Export products with our Store Manager for PrestaShop Import/Export Wizard! As you see, the export process is successful and didn't take much time and effort! Use Store Manager to save hours each day and push your business to the next level! Experience all the advantages yourself! Try Store Manager for PrestaShop now! Get a free trial at www.prestashopmanager.com !
http://monitiumworldwide.com
Discover how to create multiple income streams online with this on of a
kind wealth building platform. take your 14 free trial today.
http://www.youtube.com/watch?v=k62uRyp6hiY
Audi stellt ab dem 16. Mai am Wörthersee in Kärnten ein außerordentlich emotionales Sportgerät vor. Das Audi e-bike Wörthersee vereint Elektroantrieb und Muskelkraft. Design-Chef Wolfgang Egger: „Als High-Performance E-Bike für Sport und Tricks bündelt es die Audi-Kernkompetenzen design, ultra, e-tron und connect.“ Bei der diesjährigen Wörthersee-Tour, dem 31. Treffen der Audi-, VW-, Seat- und Skoda-Fans, hat das E-Bike seine Weltpremiere: Trial-Biker Julien Dupont und Downhill-Spezialistin Petra Bernhard demonstrieren ihre Stunt- und Streetbike-Fähigkeiten.
http://multivu.prnewswire.com/mnr/prne/audi/53820/
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Truvia®, the #1 natural zero calorie sweetener, announced the launch of a multimillion dollar integrated marketing campaign, “From Nature. For Sweetness.” The new creative campaign, kicked off on September 24th, will further drive consumer awareness, trial and adoption of Truvia® products in the U.S. Since opening the U.S. market for stevia-based sweeteners in 2008, the Truvia® brand has led the natural sweetener category and now holds a 61 percent market share.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58203-truvia-from-nature-for-sweetness-campaign-spotlights-stevia-sweetener
People of all ages and levels are welcome to try out our specialized and customized training programs as part of our 30 Day Free Trial. The quality of our curriculum and instruction, the reliability, professionalism and appearance of our academy.
The Studio365 mobile app by Live365 mobile app enables broadcasters to manage their radio stations anywhere they go. With the Studio365 mobile app you can: • Create, preview, and manage your Shout Out Messages • Set and update your pre-rolls and station ID messages • Update your profile including title, image, description, etc. • Check your listener stats in real time • Listen and share your station anywhere New features coming soon To
use the Studio365 app, a Live365 broadcasting account is required. To
learn more about broadcasting with Live365, and to get a free 7 day
personal broadcasting trial using the Live365 platform, visit
http://www.live365.com/dj
http://www.greatsouthernoutdoors.com/book_a_hunt/quail_hunting/ Sweet Home Alabama Quail Hunting Great Southern Outdoors prides itself being located in the region known as the Field Trial Capital of the World. Quail hunting in this area has been a gentlman's sport since the 1800′s when plantation owners would get involved in friendly competition. Now it has become a well liked sport by both outdoors-men and women. Great Southern Outdoors quail staff, Josh, Mark, Freeman, and Hunter enjoy the sport as much as our hunters and a little friendly competition only makes it more exciting.You are sure to have an experience of a lifetime just watching the dogs work and being in the Great Southern Outdoors.
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Off the coast of Central America, the Sea Diva, a tuna boat, sinks. Members of the crew are missing and what happened remains a mystery. As the case goes to trial, a missing crew member is believed to be at fault, but new evidence comes to light and the finger of guilt points in a completely unanticipated direction. Learn more here: http://bit.ly/1LHfMJ0
